Idiopathic Noncirrhotic Portal Hypertension

  • 文章类型: Systematic Review
    背景:窦口血管障碍(PSVD)是门静脉高压症的常见原因之一,与早期肝硬化具有重叠特征。PSVD与肝硬化的区别需要肝活检,这是侵入性的,有潜在的并发症。本系统综述旨在总结目前关于非侵入性方法区分PSVD和肝硬化的证据。
    方法:对MEDLINE电子数据库的全面搜索,Embase,和Scopus于2000年至2022年10月进行了比较PSVD和肝硬化的弹性成像和放射学特征的研究,以肝活检为金标准。
    结果:共有12项研究纳入系统评价。瞬时弹性成像(TE)作为模态在五项研究中进行了研究,磁共振弹性成像(MRE)一分为二,CT造影一分为二,对比CT和MRI一分为二,只有一个ARFI。TE和MRE均显示出显着较低的肝脏硬度测量和较高的脾硬度测量与PSVD较高的SSM/LSM比,与肝硬化相比。在放射学特征中,局灶性结节性增生样病变,门静脉异常(肝内和肝外),较大的脾脏大小有利于PSVD的诊断。相比之下,IV段的表面结节和萎缩以及I段肥大有利于肝硬化的诊断。
    结论:弹性成像和横断面成像可以帮助区分PSVD和早期肝硬化,具有良好的准确性。需要进一步的研究来评估两种模式的组合的诊断作用。
    Porto-sinusoidal vascular disorder (PSVD) is one of the common causes of portal hypertension and has overlapping features with early cirrhosis. The differentiation of PSVD from cirrhosis requires a liver biopsy, which is invasive and has potential complications. This systematic review aimed at summarizing the current evidence on the performance of noninvasive modalities for differentiating PSVD from cirrhosis.
    A comprehensive search of electronic databases of MEDLINE, Embase, and Scopus was conducted from 2000 to October 2022 for the studies comparing the elastographic and radiological features of PSVD and cirrhosis, using liver biopsy as the gold standard.
    A total of 12 studies were included in the systematic review. Transient elastography (TE) as a modality was studied in five studies, MR elastography (MRE) in two, contrast CT in two, Contrast CT and MRI in two, and ARFI in only one. Both TE and MRE showed a significantly lower liver stiffness measurement and a higher splenic stiffness measurement with a higher SSM/LSM ratio with PSVD, compared to cirrhosis. Among the radiological features, focal nodular hyperplasia-like lesions, portal vein abnormalities (intrahepatic and extrahepatic), and a larger spleen size favored a diagnosis of PSVD. In contrast, surface nodularity and atrophy of segment IV with a segment I hypertrophy favored a diagnosis of cirrhosis.
    Elastography and cross-sectional imaging can help differentiate PSVD from early cirrhosis with good accuracy. Further studies are required to assess the diagnostic role of a combination of both modalities.
    导出

    更多引用

    收藏

    翻译标题摘要

    我要上传

    求助全文

  • 文章类型: Meta-Analysis
    背景:门静脉高压症继发于肝硬化或非肝硬化原因,妊娠并发症对治疗团队构成了挑战。进行了系统评价,以确定患有门静脉高压症的女性的孕产妇和围产期结局。比较肝硬化(CPH)与非肝硬化门脉高压(NCPH)以及非肝硬化门脉纤维化(NCPF)与肝外门静脉阻塞(EHPVO)的患者的预后。
    方法:在Medline和EMBASE数据库中搜索报告妊娠合并门静脉高压的孕妇结局的研究。手工搜索相关论文和评论的参考文献列表,以获取适当的引用。提取数据来描述母体并发症,产科和新生儿结局。使用随机效应模型来得出各种结果的汇总估计,最终估计值以百分比报告,置信区间为95%(CI).累积,研究了序贯分析和敏感性分析,以评估该期间结局的时间趋势.
    结果:从26项研究中纳入了581例门脉高压患者中895例妊娠的信息。在妊娠期间诊断出门脉高压的比例为10%(95%CI4-24%)。有22例孕产妇死亡(0%,95%CI0-1%),主要是静脉曲张出血或肝功能失代偿的并发症。静脉曲张破裂出血并发14%(95%CI9-20%),在妊娠期间进行内镜干预的比例为12%(95%CI8-17%).肝功能失代偿发生在7%(95%CI3-12%)。血小板减少是最常见的并发症(41%,95%CI23-60%)。流产发生率为14%(95%CI8-20%),27%的早产(95%CI19-37%),22%的低出生体重(95%CI15-30%)。产后出血的风险更高(RR5.09,95%CI1.84-14.12),与NCPH相比,CPH患者的静脉曲张出血较低(RR0.51,95%CI0.30-0.86)。各种结果的风险在NCPF和EHPVO之间是相当的。
    结论:十分之一的妊娠合并门静脉高压症在妊娠期被诊断,血小板减少是最常见的并发症。肝脏代偿失调和静脉曲张破裂出血仍然是孕产妇死亡的最常见原因。在怀孕期间引入内窥镜手术后,出血率及其并发症的发生率降低。CPH增加产后出血的风险,而NCPH中静脉曲张出血较高。
    BACKGROUND: Portal hypertension is secondary to either cirrhotic or non-cirrhotic causes, and complicating pregnancy poses a challenge to the treating team. A systematic review was performed to determine maternal and perinatal outcomes in women with portal hypertension. Outcomes were compared among those with cirrhotic (CPH) with non-cirrhotic portal hypertension (NCPH) as well as non-cirrhotic portal fibrosis (NCPF) with extra-hepatic portal vein obstruction (EHPVO).
    METHODS: Medline and EMBASE databases were searched for studies reporting outcomes among pregnant women with portal hypertension. Reference lists from relevant papers and reviews were hand-searched for appropriate citations. Data were extracted to describe maternal complications, obstetric and neonatal outcomes. A random-effects model was used to derive pooled estimates of various outcomes, and final estimates were reported as percentages with a 95% confidence interval (CI). Cumulative, sequential and sensitivity analysis was studied to assess the temporal trends of outcomes over the period.
    RESULTS: Information on 895 pregnancies among 581 patients with portal hypertension was included from 26 studies. Portal hypertension was diagnosed during pregnancy in 10% (95% CI 4-24%). There were 22 maternal deaths (0%, 95% CI 0-1%), mostly following complications from variceal bleeding or hepatic decompensation. Variceal bleeding complicated in 14% (95% CI 9-20%), and endoscopic interventions were performed in 12% (95% CI 8-17%) during pregnancy. Decompensation of liver function occurred in 7% (95% CI 3-12%). Thrombocytopenia was the most common complication (41%, 95% CI 23-60%). Miscarriages occurred in 14% (95% CI 8-20%), preterm birth in 27% (95% CI 19-37%), and low birth weights in 22% (95% CI 15-30%). Risk of postpartum hemorrhage was higher (RR 5.09, 95% CI 1.84-14.12), and variceal bleeding was lower (RR 0.51, 95% CI 0.30-0.86) among those with CPH compared to NCPH. Risk of various outcomes was comparable between NCPF and EHPVO.
    CONCLUSIONS: One in ten pregnancies complicated with portal hypertension is diagnosed during pregnancy, and thrombocytopenia is the most common complication. Hepatic decompensation and variceal bleeding remain the most common cause of maternal deaths, with reduced rates of bleeding and its complications reported following the introduction of endoscopic procedures during pregnancy. CPH increases the risk of postpartum hemorrhage, whereas variceal bleeding is higher among NCPH.
    导出

    更多引用

    收藏

    翻译标题摘要

    我要上传

    求助全文

公众号